JPWO2019151470A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019151470A5 JPWO2019151470A5 JP2019569604A JP2019569604A JPWO2019151470A5 JP WO2019151470 A5 JPWO2019151470 A5 JP WO2019151470A5 JP 2019569604 A JP2019569604 A JP 2019569604A JP 2019569604 A JP2019569604 A JP 2019569604A JP WO2019151470 A5 JPWO2019151470 A5 JP WO2019151470A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- phenyl
- receptor
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000000018 receptor agonist Substances 0.000 claims 7
- 229940044601 receptor agonist Drugs 0.000 claims 7
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims 5
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010029113 Neovascularisation Diseases 0.000 claims 2
- 201000007527 Retinal artery occlusion Diseases 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 208000002741 leukoplakia Diseases 0.000 claims 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- 230000008728 vascular permeability Effects 0.000 claims 2
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 1
- IINUNQPYJGJCJI-UHFFFAOYSA-N 2-amino-2-[2-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]ethyl]propane-1,3-diol Chemical compound C1=C(Cl)C(CCC(CO)(CO)N)=CC=C1SC1=CC=CC(OCC=2C=CC=CC=2)=C1 IINUNQPYJGJCJI-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- NJNXCJPSMWKXHO-VIFPVBQESA-N 3-(3h-benzimidazol-5-yl)-5-[3-(trifluoromethyl)-4-[(2s)-1,1,1-trifluoropropan-2-yl]oxyphenyl]-1,2,4-oxadiazole Chemical compound C1=C(C(F)(F)F)C(O[C@@H](C)C(F)(F)F)=CC=C1C1=NC(C=2C=C3N=CNC3=CC=2)=NO1 NJNXCJPSMWKXHO-VIFPVBQESA-N 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 201000010183 Papilledema Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038886 Retinal oedema Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- GFZWHAAOIVMHOI-UHFFFAOYSA-N azetidine-3-carboxylic acid Chemical compound OC(=O)C1CNC1 GFZWHAAOIVMHOI-UHFFFAOYSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000649 photocoagulation Effects 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 201000011195 retinal edema Diseases 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018016911 | 2018-02-02 | ||
| JP2018016911 | 2018-02-02 | ||
| PCT/JP2019/003573 WO2019151470A1 (ja) | 2018-02-02 | 2019-02-01 | 眼内血管新生及び／又は眼内血管透過性亢進を伴う眼科疾患の予防又は治療のための医薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2019151470A1 JPWO2019151470A1 (ja) | 2021-02-25 |
| JPWO2019151470A5 true JPWO2019151470A5 (https=) | 2022-01-20 |
Family
ID=67479734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569604A Pending JPWO2019151470A1 (ja) | 2018-02-02 | 2019-02-01 | 眼内血管新生及び／又は眼内血管透過性亢進を伴う眼科疾患の予防又は治療のための医薬 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210113529A1 (https=) |
| EP (1) | EP3747471A4 (https=) |
| JP (1) | JPWO2019151470A1 (https=) |
| KR (1) | KR20200116953A (https=) |
| CN (1) | CN111683682A (https=) |
| AU (1) | AU2019214265A1 (https=) |
| BR (1) | BR112020015567A2 (https=) |
| CA (1) | CA3089952A1 (https=) |
| IL (1) | IL275603A (https=) |
| JO (1) | JOP20200186A1 (https=) |
| MA (1) | MA53098A (https=) |
| MX (1) | MX2020007948A (https=) |
| PH (1) | PH12020551015A1 (https=) |
| RU (1) | RU2020128700A (https=) |
| SG (1) | SG11202006255UA (https=) |
| WO (1) | WO2019151470A1 (https=) |
| ZA (1) | ZA202004327B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021148439A1 (en) * | 2020-01-21 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stimulating cerebrovascular function |
| WO2021163355A1 (en) * | 2020-02-11 | 2021-08-19 | Arena Pharmaceuticals, Inc. | Formulations and methods of treating conditions related to the s1p1 receptor |
| KR20230051154A (ko) * | 2020-06-11 | 2023-04-17 | 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 스핑고신-1-포스페이트 수용체 조절제인 핑골리모드 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물 |
| CN113082031A (zh) * | 2021-03-09 | 2021-07-09 | 温州医科大学附属眼视光医院 | 一种多巴胺d1和d2受体非选择性激动剂在作为制备治疗眼部病理性血管新生药物的应用 |
| CN119776509A (zh) * | 2023-10-08 | 2025-04-08 | 华东师范大学 | Ndufa10基因和S1pr4基因突变在肌病诊断、预测和治疗中的用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1643983B1 (en) * | 2003-06-24 | 2010-05-05 | The University of Connecticut | Methods of inhibiting vascular permeability and apoptosis |
| US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| US8022225B2 (en) | 2004-08-04 | 2011-09-20 | Taisho Pharmaceutical Co., Ltd | Triazole derivative |
| GB0504544D0 (en) | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
| EP1988083B1 (en) | 2006-02-03 | 2014-04-02 | Taisho Pharmaceutical Co., Ltd. | Triazole derivative |
| JP5218737B2 (ja) | 2006-02-06 | 2013-06-26 | 大正製薬株式会社 | スフィンゴシン−１−リン酸結合阻害物質 |
| MX2008012738A (es) * | 2006-04-03 | 2009-02-06 | Astellas Pharma Inc | Heterocompuesto. |
| EP2083862A4 (en) | 2006-10-27 | 2012-09-19 | Lpath Inc | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND DISORDERS |
| CA2666709A1 (en) | 2006-11-10 | 2008-05-29 | Genentech, Inc. | Method for treating age-related macular degeneration |
| EP2014653A1 (en) | 2007-06-15 | 2009-01-14 | Bioprojet | Novel dicarboxylic acid derivatives as S1P1 receptor agonists |
| DK2177512T3 (da) | 2007-08-01 | 2012-06-18 | Taisho Pharmaceutical Co Ltd | S1P1-bindingshæmmer |
| US8193378B2 (en) | 2008-12-05 | 2012-06-05 | Astellas Pharma Inc. | 2H-chromene compound and derivative thereof |
| CA2778611A1 (en) | 2009-10-23 | 2011-04-28 | Allergan, Inc. | Coumarin compounds as receptor modulators with therapeutic utility |
| JP5939158B2 (ja) | 2009-11-24 | 2016-06-22 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 治療的有用性を有する受容体調節物質としての新規化合物 |
| CN102711756A (zh) | 2010-01-14 | 2012-10-03 | 株式会社三和化学研究所 | 用于预防或治疗伴有眼内血管生成及/或眼内血管通透性增高的疾病的药物 |
| US8273776B2 (en) | 2010-04-16 | 2012-09-25 | Allergan, Inc | Biphenyl oxadiazole derivatives as sphingosine-1-phosphate receptors modulators |
| EP2643303A1 (en) | 2010-11-24 | 2013-10-02 | Allergan, Inc. | Modulators of s1p receptors |
| KR20130133216A (ko) | 2010-11-24 | 2013-12-06 | 알러간, 인코포레이티드 | S1p 수용체의 신규한 인돌 조절제 |
| JP2014508106A (ja) | 2010-12-03 | 2014-04-03 | アラーガン インコーポレイテッド | スフィンゴシン−１−リン酸−１受容体モジュレーターとしてのアルキンおよびアルケン誘導体 |
| WO2012105610A1 (ja) | 2011-02-02 | 2012-08-09 | 公立大学法人名古屋市立大学 | 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 |
| AU2012242807A1 (en) | 2011-04-14 | 2013-11-07 | Allergan, Inc. | Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators |
| SG194209A1 (en) | 2011-04-18 | 2013-11-29 | Allergan Inc | Substituted bicyclic methyl amine derivatives as sphingosine-1-phosphate receptors modulators |
| US9000016B2 (en) | 2012-11-05 | 2015-04-07 | Allergan, Inc. | 1,3,4-Oxadiazoles-2-thio derivatives as sphingosine-1 phosphate receptors modulators |
| US8735433B1 (en) | 2012-11-14 | 2014-05-27 | Allergan, Inc. | Aryl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators |
| WO2014130565A1 (en) | 2013-02-20 | 2014-08-28 | Allergan, Inc. | Substituted diaryl azetidine derivatives as sphingosine receptor modulators |
| JP6294872B2 (ja) * | 2013-04-26 | 2018-03-14 | 国立大学法人京都大学 | 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物 |
| JP2018016911A (ja) | 2016-07-28 | 2018-02-01 | 村田機械株式会社 | 解析装置 |
-
2019
- 2019-02-01 JP JP2019569604A patent/JPWO2019151470A1/ja active Pending
- 2019-02-01 KR KR1020207024569A patent/KR20200116953A/ko not_active Ceased
- 2019-02-01 CN CN201980010708.6A patent/CN111683682A/zh active Pending
- 2019-02-01 JO JOP/2020/0186A patent/JOP20200186A1/ar unknown
- 2019-02-01 MA MA053098A patent/MA53098A/fr unknown
- 2019-02-01 RU RU2020128700A patent/RU2020128700A/ru unknown
- 2019-02-01 AU AU2019214265A patent/AU2019214265A1/en not_active Abandoned
- 2019-02-01 EP EP19747229.3A patent/EP3747471A4/en not_active Withdrawn
- 2019-02-01 BR BR112020015567-5A patent/BR112020015567A2/pt not_active IP Right Cessation
- 2019-02-01 MX MX2020007948A patent/MX2020007948A/es unknown
- 2019-02-01 CA CA3089952A patent/CA3089952A1/en active Pending
- 2019-02-01 SG SG11202006255UA patent/SG11202006255UA/en unknown
- 2019-02-01 WO PCT/JP2019/003573 patent/WO2019151470A1/ja not_active Ceased
- 2019-02-01 US US16/966,757 patent/US20210113529A1/en not_active Abandoned
-
2020
- 2020-06-23 IL IL275603A patent/IL275603A/en unknown
- 2020-06-29 PH PH12020551015A patent/PH12020551015A1/en unknown
- 2020-07-14 ZA ZA2020/04327A patent/ZA202004327B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019151470A5 (https=) | ||
| RU2020128700A (ru) | Лекарственное средство для профилактики или лечения глазного заболевания, связанного с повышенной внутриглазной неоваскуляризацией и/или проницаемостью внутриглазных сосудов | |
| RU2419624C2 (ru) | Сульфонамидные производные как активаторы гликокиназы, применимые для лечения диабета типа 2 | |
| JP6243882B2 (ja) | 眼球浮腫、血管新生および関連疾患を処置するための組成物および方法 | |
| RU2379299C2 (ru) | Производные 5-(бенз-(z)-илиден)тиазолидин-4-она и их применение в качестве иммуносупрессорных агентов | |
| RU2492167C2 (ru) | Производные аминотриазола в качестве агонистов alх | |
| JP2006506340A5 (https=) | ||
| JP2006502134A5 (https=) | ||
| JP2015509510A5 (https=) | ||
| US20020022622A1 (en) | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | |
| RU2481330C2 (ru) | Азотсодержащее ароматическое гетероциклическое соединение | |
| JP2016516026A5 (https=) | ||
| KR960007587A (ko) | 치환 비페닐 이속사졸 술폰아미드 | |
| JP2004517080A5 (https=) | ||
| JP2010540462A5 (https=) | ||
| JP2017519836A5 (https=) | ||
| JP2021533152A5 (https=) | ||
| IL276624B2 (en) | Triazine derivatives for the treatment of neurotrophin-related diseases | |
| JP2014513122A5 (https=) | ||
| HRP20200606T1 (hr) | Derivati fenila kao agonisti kanabinoidnog receptora 2 | |
| RU2013152961A (ru) | Изоксазолины в качестве терапевтических агентов | |
| RU2018126349A (ru) | Индановые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
| JPWO2021229152A5 (https=) | ||
| CA2708418A1 (en) | Oxazolidinones for the treatment and/or prophylaxis of heart failure | |
| CA2449578A1 (en) | Pyrrolidine oxadiazole- and thiadiazole derivatives |